Grand Pharma has recently completed the registration of changes in 100% equity interests in Tianjin Tanabe Seiyaku Co, Ltd. (“Tianjin Tanabe”), and Nanchang Baiji Pharmaceutical Co., Ltd. * (南昌百濟製藥有限公司) and Jiangxi Baian Baiyu Pharmaceutical Technology Co., Ltd.* (江西百安百煜醫藥科技有限公司, collectively referred to as “Baiji Pharmaceutical”), respectively. These two acquisitions will further deepen the Group’s industrial strategic plan in the cerebro-cardiovascular emergency segment and the respiratory and critical and severe disease segment.
Tianjin Tanabe is one of Mitsubishi Tanabe Pharma Corporation (“MTPC”)’s core enterprises in China. It mainly engages in the production and sales of high-quality original drugs in the fields of cerebrocardiovascular, endocrine metabolism, gastrointestinal and other chronic diseases. Tianjin Tanabe has multiple Good Manufacture Practice of Medical Products (GMP) certified production lines. Its product type covers tablets, capsules, granules, injections and other dosage forms, with more than 10 products on sale, involving hypertension, angina pectoris, coronary heart disease, diabetes, gastrointestinal diseases and other chronic disease indications. Its core products, such as Herbesser®(合貝爽®及合心 爽®), Anplag®, etc., have been included in many authoritative clinical guidelines at home and abroad, with clear clinical efficacy and high safety, continuously providing high-quality treatment methods for the growing clinical needs of patients with chronic diseases in China.
Beijing Grand Jiuhe Pharmaceutical Co., Ltd.* (北京遠大九和藥業有限公司), a subsidiary of the
Group, has recently acquired 100% equity of Baiji Pharmaceutical and obtained its technologically
leading nasal spray preparations platform for approximately RMB 260 million. This acquisition is a
major strategic plan of the Group in the respiratory and critical and severe disease segment. Baiji
Pharmaceutical’s products will form a product portfolio with the Group’s Ryaltris® Compound Nasal
Spray to fully meet the medication needs of patients with mild, moderate and severe allergic rhinitis
(“AR”), and at the same time, will further improve the construction of the Group’s inhaled preparation
platform in the field of respiratory.
This acquisition of Baiji Pharmaceutical is a major industrial strategic plan of the Group in the respiratory and critical and severe disease segment. After the completion of this acquisition, the Group will become one of the companies with the most comprehensive product pipeline for the treatment of AR in China, and will have a domestically leading technology platform for nasal spray preparations. The Group will utilize its strong R&D and registration capabilities to focus on promoting the clinical registration process of Fluticasone Propionate Nasal Spray and Mometasone Furoate Nasal Spray. Meanwhile, it will accelerate the market expansion and promotion of Budesonide nasal spray, and benefit more patients with AR. In addition, products from Baiji Pharmaceutical’s nasal spray preparation platform will form a product portfolio with Enerzair® Breezhaler® (indacaterol acetate, glycopyrronium bromide and mometasone furoate powder for inhalation II) and Atectura® Breezhaler® (indacaterol acetate and mometasone furoate powder for inhalation II, III), to fully promote the construction of the Group’s inhaled preparation platform in the field of respiratory, further improve the comprehensive strategic plan in the production, research and sales in the direction of inhaled preparations in respiratory and critical and severe disease segment, and consolidate and enhance the Group’s comprehensive market competitiveness.
